EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Shanghai Fosun Pharmaceutical (Group) Co's enterprise value is HK$78,761 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$45,577 Mil. Therefore, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-Revenue for today is 1.73.
The historical rank and industry rank for Shanghai Fosun Pharmaceutical (Group) Co's EV-to-Revenue or its related term are showing as below:
HKSE:02196'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.17 Med: 4.35 Max: 7.8
Current: 1.73
During the past 13 years, the highest EV-to-Revenue of Shanghai Fosun Pharmaceutical (Group) Co was 7.80. The lowest was 2.17. And the median was 4.35.
HKSE:02196's EV-to-Revenue is ranked better than 59.84% of 1026
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs HKSE:02196: 1.73
As of today (2024-04-23), Shanghai Fosun Pharmaceutical (Group) Co's stock price is HK$11.76.
Shanghai Fosun Pharmaceutical (Group) Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$16.87. Therefore, Shanghai Fosun Pharmaceutical (Group) Co's PS Ratio for today is 0.70.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-Revenue Historical Data
The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
3.06
5.26
3.70
2.66
2.35
Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
2.66
2.50
2.48
2.42
2.35
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-Revenue Distribution
For the Drug Manufacturers industry and Healthcare sector, Shanghai Fosun Pharmaceutical (Group) Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Shanghai Fosun Pharmaceutical (Group) Co's EV-to-Revenue falls into.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-Revenue Calculation
Shanghai Fosun Pharmaceutical (Group) Co's current Enterprise Value is HK$78,761 Mil.
Shanghai Fosun Pharmaceutical (Group) Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$45,577 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) EV-to-Revenue Explanation
Shanghai Fosun Pharmaceutical (Group) Co's share price for today is HK$11.76.
Shanghai Fosun Pharmaceutical (Group) Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$16.87.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Shanghai Fosun Pharmaceutical (Group) Co (HKSE:02196) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02196 has been successfully added to your 